Publications of Institute of Radiopharmaceutical Cancer Research

28 Publications

2021

Pharmacokinetic studies of [⁶⁸Ga]Ga‑PSMA‑11 in patients with biochemical recurrence of prostate cancer: detection, differences in temporal distribution and kinetic modelling by tissue type

Strauss, D. S.; Sachpekidis, C.; Kopka, K.; Pan, L.; Haberkorn, U.; Dimitrakopoulou‑Strauss, A.


Aktuelle Entwicklungen aus den Radiopharmazeutischen Wissenschaften für theranostische Anwendungen - Editorial

Mamat, C.; Kopka, K.


Predicting the Risk of Metastases by PSMA-PET/CT—Evaluation of 335 Men with Treatment-Naïve Prostate Carcinoma.

Koerber, S.; Boesch, J.; Kratochwil, C.; Schlampp, I.; Ristau, J.; Winter, E.; Zschaebitz, S.; Hofer, L.; Herfarth, K.; Kopka, K.; Holland-Letz, T.; Jaeger, D.; Hohenfellner, M.; Haberkorn, U.; Debus, J.; Giesel, F.


Development and Validation of a GMP-Compliant High-Pressure Liquid Chromatography Method for the Determination of the Chemical and Radiochemical Purity of [18F]PSMA-1007, a PET Tracer for the Imaging of Prostate Cancer

Katzschmann, I.; Marx, H.; Kopka, K.; Hennrich, U.


Synthesis and application of a thiol-reactive HBED-type chelator for development of easy-toproduce Ga-radiopharmaceutical kits and imaging probes

Klika, K.; Da, P. C.; Kopka, K.; Smith, G.; Makarem, A.


Development of an 18F-labelled irreversible inhibitor of transglutaminase 2 as radiometric tool for quantitative expression profiling in cells and tissues

Wodtke, R.; Wodtke, J.; Hauser, S.; Laube, M.; Bauer, D.; Rothe, R.; Neuber, C.; Pietsch, M.; Kopka, K.; Pietzsch, J.; Löser, R.


Highlight selection of radiochemistry and radiopharmacy developments by editorial board

Aime, S.; Al-Qahtani, M.; Behe, M.; Bormans, G.; Carlucci, G.; Dasilva, J.; Decristoforo, C.; Duatti, A.; Elsinga, P.; Kopka, K.; Li, X.; Liu, Z.; Mach, R.; Middel, O.; Passchier, J.; Patt, M.; Penuelas, I.; Rey, A.; Scott, P.; Todde, S.; Toyohara, J.; Vugts, D.; Yang, Z.


Towards Targeted Alpha Therapy with Actinium 225: Chelators for Mild Condition Radiolabeling and Targeting PSMA – a Proof of Concept Study

Reissig, F.; Bauer, D.; Zarschler, K.; Novy, Z.; Bendova, K.; Kopka, K.; Pietzsch, H.-J.; Petrik, M.; Mamat, C.


Cytoplasmic localization of prostate-specific membrane antigen inhibitors may confer advantages for targeted cancer therapies.

Matthias, J.; Engelhardt, J.; Schäfer, M.; Bauder-Wüst, U.; Meyer, P.; Haberkorn, U.; Eder, M.; Kopka, K.; Hell, S.; Eder, A.


The Impact of Barium Isotopes in Radiopharmacy and Nuclear Medicine – from Past to Presence

Reissig, F.; Kopka, K.; Mamat, C.


Highlight selection of radiochemistry and radiopharmacy developments by editorial board (January-June 2020).

Al-Qahtani, M.; Behe, M.; Bormans, G.; Carlucci, G.; Dasilva, J.; Decristoforo, C.; Elsinga, P.; Kopka, K.; Li, X.; Mach, R.; Middel, O.; Passchier, J.; Patt, M.; Penuelas, I.; Rey, A.; Scott, P.; Todde, S.; Toyohara, J.; Vugts, D.


Die Bedeutung des Elementes Barium in der Nuklearmedizin

Reissig, F.; Kopka, K.; Mamat, C.


The PSMA-11-derived hybrid molecule PSMA-914 specifically identifies prostate cancer by preoperative PET/CT and intraoperative fluorescence imaging

Eder, A.; Omrane, M.; Stadlbauer, S.; Roscher, M.; Khoder, W.; Gratzke, C.; Kopka, K.; Eder, M.; Meyer, P.; Jilg, C.; Ruf, J.


Development of the First Potential Nonpeptidic Positron Emission Tomography Tracer for the Imaging of CCR2 Receptors

Wagner, S.; De, M. G. F.; Silva, D.; Ortiz, Z. N.; Zweemer, A.; Hermann, S.; De, M. M.; Koch, M.; Weiss, C.; Schepmann, D.; Heitman, L.; Tschammer, N.; Kopka, K.; Junker, A.


On the consensus nomenclature rules for radiopharmaceutical chemistry – reconsideration of radiochemical conversion

Herth, M.; Ametamey, S.; Antuganov, D.; Bauman, A.; Berndt, M.; Brooks, A.; Bormans, G.; Choe, Y.; Gillings, N.; Häfeli, U.; James, M.; Kopka, K.; Kramer, V.; Krasikova, R.; Madsen, J.; Mu, L.; Neumaier, B.; Piel, M.; Rösch, F.; Ross, T.; Schibli, R.; Scott, P.; Shalgunov, V.; Vasdev, N.; Wadsak, W.; Zeglis, B.


Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

Koerber, S. A.; Sprute, K.; Kratochwil, C.; Winter, E.; Haefner, M. F.; Katayama, S.; Schlampp, I.; Herfarth, K.; Kopka, K.; Afshar-Oromieh, A.; Zschaebitz, S.; Holland-Letz, T.; Choyke, P. L.; Jaeger, D.; Hohenfellner, M.; Haberkorn, U.; Debus, J.; Giesel, F. L.


2020

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues

Sinnes, J.; Bauder-Wüst, U.; Schäfer, M.; Moon, E.; Kopka, K.; Rösch, F.


Development of PSMA-1007 - Related Series of 18F-Labeled Glu-ureido type PSMA inhibitors.

Cardinale, J.; Roscher, M.; Schaefer, M.; Geerlings, M.; Benešová, M.; Bauder-Wüst, U.; Remde, Y.; Eder, M.; Novakova, Z.; Motlová, L.; Bařinka, C.; Giesel, F.; Kopka, K.


Live-cell Imaging with Aspergillus Fumigatus-specific fluorescent Siderophore Conjugates

Pfister, J.; Lichius, A.; Summer, D.; Haas, H.; Kanagasundaram, T.; Kopka, K.; Decristoforo, C.


Synthesis, characterization and evaluation of 68Ga labelled monomeric and dimeric quinazoline derivatives of the HBED-CC chelator targeting the epidermal growth factor receptor

Liolios, C.; Shegani, A.; Roupa, I.; Kiritsis, C.; Makarem, A.; Paravatou-Petsotas, M.; Pelecanou, M.; Bouziotis, P.; Papadopoulos, M.; Kopka, K.; Pirmettis, I.


Recent insights in barium-131 as a diagnostic match for radium-223: cyclotron production, separation, labeling and imaging

Reissig, F.; Bauer, D.; Ullrich, M.; Kreller, M.; Pietzsch, J.; Mamat, C.; Kopka, K.; Pietzsch, H.-J.; Walther, M.


Deuteration versus ethylation – strategies to improve the metabolic fate of a 18F-labeled celecoxib derivative

Laube, M.; Gassner, C.; Neuber, C.; Wodtke, R.; Ullrich, M.; Haase-Kohn, C.; Löser, R.; Köckerling, M.; Kopka, K.; Knieß, T.; Hey-Hawkins, E.; Pietzsch, J.


Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination

Naka, S.; Watabe, T.; Kurimoto, K.; Uemura, M.; Soeda, F.; Neels, O.; Kopka, K.; Tatsumi, M.; Kato, H.; Nonomura, N.; Shimosegawa, E.; Cardinale, J.; Giesel, F.; Hatazawa, J.


Rhenium and technetium-complexed silicon rhodamines as near-infrared imaging probes for bimodal SPECT- and optical imaging

Kanagasundaram, T.; Kramer, C. S.; Boros, E.; Kopka, K.


Interprofessionelle Kooperation in klinischen Studien. Zunehmender Bedarf, Komplexität und Anregungen am Beispiel einer prospektiv-onkologischen Multicenter-Studie.

Zippel, C.; Giesel, F.; Kopka, K.


Sub-10 nm Radiolabeled Barium Sulfate Nanoparticles as Carriers for Theranostic Applications and Targeted Alpha Therapy

Reissig, F.; Zarschler, K.; Hübner, R.; Pietzsch, H.-J.; Kopka, K.; Mamat, C.


Current status of PSMA-radiotracers for prostate cancer: data analysis of prospective trials listed on ClinicalTrials.gov

Zippel, C.; Ronski, S. C.; Bohnet-Joschko, S.; Giesel, F. L.; Kopka, K.


2019

A theranostic PSMA ligand for PET imaging and retargeting of T cells expressing the universal chimeric antigen receptor UniCAR

Arndt, C.; Feldmann, A.; Koristka, S.; Schäfer, M.; Bergmann, R.; Metwasi, N.; Berndt, N.; Bachmann, D.; Kegler, A.; Schmitz, M.; Puentes-Cala, E.; Soto, J. A.; Ehninger, G.; Pietzsch, J.; Liolios, C.; Wunderlich, G.; Kotzerke, J.; Kopka, K.; Bachmann, M.